Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Sparsentan has emerged as a promising therapeutic option for IgA nephropathy (IgAN) while Targeted-release formulation (Trf-) Budesonid is an established treatment for patients with persistent proteinuria and evidence of inflammation. However, evidence regarding the sequential or combined use of both therapies in real-world settings remains scarce. In this subanalysis of our managed access program analysis for sparsentan, we present the 1-year follow-up of patients who received Trf-Budesonid prior, during, or after initiation of sparsentan.
We identified n=7 patients with biopsy-proven IgAN and available follow-up for at least 12 months. All patients had been on stable SGLT2 inhibition and maximally tolerated RAAS blockade at baseline. Four patients had concomitant, while 3 patients hat preceding Trf-Budesonid therapy. Proteinuria trajectories were assessed at prespecified visits up to 12 months.
At baseline, median (IQR) age was 27 (26–30) years, 71% were male gender, median eGFR was 38 (34–48) ml/min/1.73m², and median proteinuria (UPCR) was 1.80 (1.67–4.16) g/g creatinine. Following sparsentan initiation, UPCR declined early and further decreased in patients with additional Trf-Budesonid exposure (Figure 1). At 12 months, median (IQR) UPCR was 0.57 (0.44–0.78) g/g, corresponding to a relative reduction of 68%. Three of seven patients (42%) achieved complete remission (UPCR <0,3 g/g), and additional 3 patients reached partial remission (UPCR <1 g/g) during 12-month treatment. No unexpected adverse events occurred.
Our 1-year real-world subanalysis suggests that sequential or combined therapy with sparsentan and Trf-Budesonid exerts additive and sustained antiproteinuric effects in the treatment of IgAN.
